<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285582</url>
  </required_header>
  <id_info>
    <org_study_id>1000045224</org_study_id>
    <nct_id>NCT02285582</nct_id>
  </id_info>
  <brief_title>International Rare Histiocytic Disorders Registry (IRHDR)</brief_title>
  <acronym>IRHDR</acronym>
  <official_title>International Rare Histiocytic Disorders Registry (IRHDR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more&#xD;
      organs by non-LCH histiocytes. They can range from localized disease that resolves&#xD;
      spontaneously, to progressive disseminated forms that can be sometimes life-threatening.&#xD;
      Since they are extremely rare, there is limited understanding of their causes and best&#xD;
      treatment options. Physicians, patients and parents of children with RHDs frequently consult&#xD;
      members of the Histiocyte Society regarding the best management of these disorders. Very&#xD;
      often, no specific recommendation can be made due to the lack of prospective outcome data, or&#xD;
      even large retrospective case series. The creation of an international rare histiocytic&#xD;
      disorders registry (IRHDR) could facilitate a uniform diagnosis of the RHDs, as well as the&#xD;
      collection and analysis of the clinical, epidemiological, treatment and survival data of&#xD;
      patients with RHD. The registry may also lead to future therapeutic recommendations, provide&#xD;
      a framework for future clinical trials and create excellent research opportunities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Histiocytoses are rare diseases caused by an excess of cells called Histiocytes, which can&#xD;
      infiltrate the skin, bones, lungs, liver, spleen and the central nervous system. These&#xD;
      disorders can range from localized involvement that resolves spontaneously, to progressive&#xD;
      disseminated forms that can be debilitating and sometimes life-threatening. The rare&#xD;
      histiocytic disorders (RHD), or non-Langerhans cell disorders, are a diverse group of&#xD;
      disorders defined by the accumulation of histiocytes that do not meet the criteria for&#xD;
      Langerhans cell histiocytosis (LCH) or hemophagocytic lymphohistiocytosis (HLH). They&#xD;
      include: Juvenile xanthogranuloma family, Erdheim-Chester disease, Multifocal&#xD;
      Reticulohistiocytosis, Rosai-Dorfman disease and the Malignant Histiocytoses. Since they are&#xD;
      so rare, there is limited understanding of their causes and treatments. Physicians, patients&#xD;
      and parents of children with rare histiocytoses frequently consult members of the Histiocyte&#xD;
      Society on the management of these disorders. Very often, no specific recommendation about&#xD;
      treatment can be made due to the lack of prospective outcome data for these rare entities.&#xD;
      The creation of an International Rare Histiocytic Disorders Registry (IRHDR) will facilitate&#xD;
      a uniform diagnosis of the RHD's, as well as the collection and analysis of the clinical,&#xD;
      epidemiological, treatment and survival data of patients with RHD. The registry will also&#xD;
      provide expert pathology reviews and may lead to future therapeutic recommendations.&#xD;
      Furthermore, the IRHDR can provide a framework for future clinical trials, thus, creating&#xD;
      excellent research opportunities. Lastly, a de-identified link between clinical data and&#xD;
      companion biology studies can potentially be accomplished in the future through the IRHDR.&#xD;
      This may further help in understanding the etiology of these rare diseases, as well as&#xD;
      identifying potential therapeutic targets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Collecting data on disease presentation, treatments used and treatment outcomes over time for patients diagnosed with RHD to better understand the diseases and optimize the treatments</measure>
    <time_frame>Data will be analysed on average yearly, the registry will be ongoing for 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Develop treatment guidelines for the RHD based on solid clinical trial data</measure>
    <time_frame>Data will be analysed on average yearly, the registry will be ongoing for 10 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rare Histiocytic Disorders (RHDs)</condition>
  <condition>Juvenile Xanthogranuloma (JXG)</condition>
  <condition>Reticulohistiocytoma (Epithelioid Histiocytoma)</condition>
  <condition>Xanthoma Disseminatum (XD)</condition>
  <condition>Multicentric Reticulohistiocytosis (MRH)</condition>
  <condition>Systemic Juvenile Xanthogranuloma</condition>
  <condition>Erdheim-Chester Disease (ECD)</condition>
  <condition>Multi-system Rosai-Dorfman Disease (RDD)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Registry study</intervention_name>
    <description>No intervention.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with rare histiocytic disorder.&#xD;
&#xD;
        Rare histiocytic disorders include:&#xD;
&#xD;
          1. Cutaneous non-LCH: such as the Juvenile Xanthogranuloma (JXG) family and&#xD;
             reticulohistiocytoma (epithelioid histiocytoma).&#xD;
&#xD;
          2. Cutaneous with a major systemic component&#xD;
&#xD;
               -  Xanthoma disseminatum (XD)&#xD;
&#xD;
               -  Multicentric reticulohistiocytosis (MRH)&#xD;
&#xD;
          3. Systemic non-LCH&#xD;
&#xD;
               -  Systemic juvenile xanthogranuloma&#xD;
&#xD;
               -  Erdheim-Chester disease (ECD)&#xD;
&#xD;
               -  Multi-system Rosai-Dorfman disease (RDD).&#xD;
&#xD;
          4. Malignant Histiocytoses&#xD;
&#xD;
               -  Histiocytic sarcoma&#xD;
&#xD;
               -  Langerhans cell sarcoma&#xD;
&#xD;
               -  Interdigitating dendritic cell sarcoma&#xD;
&#xD;
               -  Follicular dendritic cell sarcoma&#xD;
&#xD;
               -  Indeterminate dendritic cell tumour&#xD;
&#xD;
               -  Fibroblastic reticular cell tumour&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any age at diagnosis.&#xD;
&#xD;
          -  Diagnosis of a rare histiocytic disorder, established before or after the opening of&#xD;
             the registry.&#xD;
&#xD;
          -  Cases diagnosed from January - 01- 1995 until the present time and prospectively.&#xD;
&#xD;
          -  Suitable pathology sample available for central review.&#xD;
&#xD;
          -  Signed informed consent by a patient, or parent/legal guardian.&#xD;
&#xD;
          -  Cognitively impaired patients can be included after consent by legal guardian/parent.&#xD;
&#xD;
          -  Deceased patients can be included provided that they are contacted at least 6 months&#xD;
             after the death of their child and not on their child's birthday or anniversary of&#xD;
             death.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Informed consent has not been signed.&#xD;
&#xD;
          -  Diagnosis other than RHD.&#xD;
&#xD;
          -  Patients with no pathology sample available for central review.&#xD;
&#xD;
          -  Cases diagnosed before the year 1995&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oussama Abla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rima Jubran, MD</last_name>
      <phone>323-361-4624</phone>
    </contact>
    <investigator>
      <last_name>Rima Jubran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Children's Hospital</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Samuel, MD</last_name>
      <phone>559-353-5488</phone>
    </contact>
    <investigator>
      <last_name>David Samuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Diamond, MD</last_name>
      <phone>212-610-0188</phone>
    </contact>
    <investigator>
      <last_name>Eli Diamond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Vaiselbuh, MD</last_name>
      <phone>718-226-6129</phone>
    </contact>
    <investigator>
      <last_name>Sarah Vaiselbuh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional de Pediatria Garrahan</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Braier, MD</last_name>
      <phone>5411 41226254</phone>
    </contact>
    <investigator>
      <last_name>Jorge Braier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ELISABETHINEN Hospital Linz GmbH</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Girschikofsky, MD</last_name>
      <phone>0043 732 7676 - 4425</phone>
    </contact>
    <investigator>
      <last_name>Michael Girschikofsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oussama Abla, MD</last_name>
      <phone>416-813-7879</phone>
      <email>oussama.abla@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jill Beckley</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>202043</phone_ext>
      <email>jill.beckley@sickkids.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie Carret, MD</last_name>
      <email>anne-sophie.carret@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Anne-Sophie Carret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zdenka Křenová, MD</last_name>
      <email>Krenova.Z@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Zdenka Křenová, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carl Friedrich Classen, MD</last_name>
      <email>carl-friedrich.classen@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Carl Friedrich Classen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Meyer</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Sieni, MD</last_name>
      <email>elena.sieni@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Elena Sieni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Health Institute</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Gryniewicz-Kwiatkowska, MD</last_name>
      <email>O.Gryniewicz@IPCZD.PL</email>
    </contact>
    <investigator>
      <last_name>Olga Gryniewicz-Kwiatkowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morozov Children's Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gleb Bronin, MD</last_name>
      <email>gleb-bronin@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Gleb Bronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Itziar Astigarraga, MD</last_name>
      <phone>34 946006000</phone>
    </contact>
    <investigator>
      <last_name>Itziar Astigarraga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005 Sep;45(3):256-64. Review.</citation>
    <PMID>15547923</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Oussama Abla</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytoma</mesh_term>
    <mesh_term>Erdheim-Chester Disease</mesh_term>
    <mesh_term>Histiocytosis, Sinus</mesh_term>
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Xanthogranuloma, Juvenile</mesh_term>
    <mesh_term>Histiocytosis, Non-Langerhans-Cell</mesh_term>
    <mesh_term>Xanthomatosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

